ABBOTT LABORATORIES Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ABBOTT LABORATORIES (ABT) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $6.93 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-02-17
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was $1.99B, a 7.83% decline year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was $2.10B, a 70.45% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-06-30 was $1.19B, a 121.42% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-03-31 was $1.79B, a 229.60% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $6.93B, a 1.95% decline from fiscal 2021.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $7.07B, a 58.15% increase from fiscal 2020.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $4.47B, a 21.26% increase from fiscal 2019.
- ABBOTT LABORATORIES income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was $3.69B, a 57.97% increase from fiscal 2018.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $6.93B 10-K · filed 2023-02-17 | |||||||
| 2021-12-31 | $1.99B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $4.09B derived: sum of 2 quarters · filed 2023-02-17 | $5.28B derived: sum of 3 quarters · filed 2023-02-17 | $7.07B 10-K · filed 2023-02-17 | ||||
| 2021-09-30 | $2.10B 10-Q · filed 2021-11-03 | $3.29B derived: sum of 2 quarters · filed 2021-11-03 | $5.08B 10-Q · filed 2021-11-03 | $7.24B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $1.19B 10-Q · filed 2021-08-04 | $2.98B 10-Q · filed 2021-08-04 | $5.14B derived: sum of 3 quarters · filed 2023-02-17 | $6.37B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $1.79B 10-Q · filed 2021-05-05 | $3.95B derived: sum of 2 quarters · filed 2023-02-17 | $5.18B derived: sum of 3 quarters · filed 2023-02-17 | $5.72B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $2.16B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $3.39B derived: sum of 2 quarters · filed 2023-02-17 | $3.93B derived: sum of 3 quarters · filed 2023-02-17 | $4.47B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $1.23B 10-Q · filed 2021-11-03 | $1.77B derived: sum of 2 quarters · filed 2021-11-03 | $2.31B 10-Q · filed 2021-11-03 | $3.36B derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $537.00M 10-Q · filed 2021-08-04 | $1.08B 10-Q · filed 2021-08-04 | $2.13B derived: sum of 3 quarters · filed 2021-08-04 | $3.09B derived: sum of 4 quarters · filed 2021-08-04 | ||||
| 2020-03-31 | $544.00M 10-Q · filed 2021-05-05 | $1.59B derived: sum of 2 quarters · filed 2021-05-05 | $2.55B derived: sum of 3 quarters · filed 2021-05-05 | $3.56B derived: sum of 4 quarters · filed 2021-05-05 | ||||
| 2019-12-31 | $1.05B 10-K · filed 2020-02-21 | $2.01B derived: sum of 2 quarters · filed 2020-11-04 | $3.02B derived: sum of 3 quarters · filed 2020-11-04 | $3.69B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $960.00M 10-Q · filed 2020-11-04 | $1.97B derived: sum of 2 quarters · filed 2020-11-04 | $2.64B 10-Q · filed 2020-11-04 | $3.29B derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $1.01B 10-Q · filed 2020-07-29 | $1.68B 10-Q · filed 2020-07-29 | $2.33B derived: sum of 3 quarters · filed 2020-07-29 | $2.88B derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $672.00M 10-Q · filed 2020-04-29 | $1.33B derived: sum of 2 quarters · filed 2020-04-29 | $1.88B derived: sum of 3 quarters · filed 2020-04-29 | $2.60B derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-31 | $655.00M 10-K · filed 2020-02-21 | $1.21B derived: sum of 2 quarters · filed 2020-02-21 | $1.93B derived: sum of 3 quarters · filed 2020-02-21 | $2.33B 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $552.00M 10-K · filed 2020-02-21 | $1.27B derived: sum of 2 quarters · filed 2020-02-21 | $1.68B 10-Q · filed 2019-10-31 | $815.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $718.00M 10-K · filed 2020-02-21 | $1.13B 10-Q · filed 2019-07-31 | $263.00M derived: sum of 3 quarters · filed 2020-02-21 | $824.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $409.00M 10-K · filed 2020-02-21 | -$455.00M derived: sum of 2 quarters · filed 2020-02-21 | $106.00M derived: sum of 3 quarters · filed 2020-02-21 | $376.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | -$864.00M 10-K · filed 2019-02-22 | -$303.00M derived: sum of 2 quarters · filed 2019-02-22 | -$33.00M derived: sum of 3 quarters · filed 2019-02-22 | $353.00M 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $561.00M 10-K · filed 2019-02-22 | $831.00M derived: sum of 2 quarters · filed 2019-02-22 | $1.22B 10-Q · filed 2018-10-31 | $1.98B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $270.00M 10-K · filed 2019-02-22 | $656.00M 10-Q · filed 2018-08-01 | $1.42B derived: sum of 3 quarters · filed 2019-02-22 | $1.06B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $386.00M 10-K · filed 2019-02-22 | $1.15B derived: sum of 2 quarters · filed 2019-02-22 | $794.00M derived: sum of 3 quarters · filed 2019-02-22 | $1.39B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $765.00M 10-K · filed 2018-02-16 | $875.00M 10-K · filed 2017-02-17 | $408.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.01B derived: sum of 3 quarters · filed 2018-02-16 | $1.06B 10-K · filed 2019-02-22 | |||
| 2016-09-30 | -$357.00M 10-K · filed 2018-02-16 | $242.00M derived: sum of 2 quarters · filed 2018-02-16 | $298.00M 10-Q · filed 2017-11-02 | $993.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $599.00M 10-K · filed 2018-02-16 | $655.00M 10-Q · filed 2017-08-02 | $1.35B derived: sum of 3 quarters · filed 2018-02-16 | $1.95B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $56.00M 10-K · filed 2018-02-16 | $751.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.35B derived: sum of 3 quarters · filed 2018-02-16 | $2.13B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $695.00M 10-K · filed 2017-02-17 | $1.29B derived: sum of 2 quarters · filed 2017-02-17 | $2.08B derived: sum of 3 quarters · filed 2017-02-17 | $2.61B 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $596.00M 10-K · filed 2017-02-17 | $1.38B derived: sum of 2 quarters · filed 2017-02-17 | $1.91B 10-Q · filed 2016-11-03 | $2.54B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $786.00M 10-K · filed 2017-02-17 | $1.31B 10-Q · filed 2016-08-03 | $1.95B derived: sum of 3 quarters · filed 2017-02-17 | $2.39B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $529.00M 10-K · filed 2017-02-17 | $1.16B derived: sum of 2 quarters · filed 2017-02-17 | $1.60B derived: sum of 3 quarters · filed 2017-02-17 | $2.03B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $634.00M 10-K · filed 2016-02-19 | $1.07B derived: sum of 2 quarters · filed 2016-02-19 | $1.50B derived: sum of 3 quarters · filed 2016-02-19 | $1.72B 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $438.00M 10-K · filed 2016-02-19 | $440.00M 10-Q · filed 2014-11-06 | $863.00M derived: sum of 2 quarters · filed 2016-02-19 | $1.09B 10-Q · filed 2015-11-05 | $1.09B 10-Q · filed 2014-11-06 | $1.57B derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-06-30 | $425.00M 10-K · filed 2016-02-19 | $460.00M 10-Q · filed 2014-08-05 | $649.00M 10-Q · filed 2015-08-04 | $799.00M 10-Q · filed 2014-08-05 | $1.13B derived: sum of 3 quarters · filed 2016-02-19 | $1.78B derived: sum of 4 quarters · filed 2016-02-19 | ||
| 2014-03-31 | $224.00M 10-K · filed 2016-02-19 | $339.00M 10-Q · filed 2014-05-07 | $707.00M derived: sum of 2 quarters · filed 2016-02-19 | $1.35B derived: sum of 3 quarters · filed 2016-02-19 | $1.75B derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | $483.00M 10-K · filed 2015-02-27 | $589.00M 10-K · filed 2014-02-21 | $1.13B derived: sum of 2 quarters · filed 2015-02-27 | $1.52B derived: sum of 3 quarters · filed 2015-02-27 | $1.99B 10-K · filed 2016-02-19 | $2.38B 10-K · filed 2014-02-21 | ||
| 2013-09-30 | $644.00M 10-K · filed 2015-02-27 | $772.86M 10-Q · filed 2013-11-07 | $1.04B derived: sum of 2 quarters · filed 2015-02-27 | $1.50B 10-Q · filed 2014-11-06 | $1.79B 10-Q · filed 2013-11-07 | $983.00M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $397.00M 10-K · filed 2015-02-27 | $476.06M 10-Q · filed 2013-08-06 | $1.02B 10-Q · filed 2014-08-05 | $1.02B 10-Q · filed 2013-08-06 | $339.00M derived: sum of 3 quarters · filed 2015-02-27 | $678.00M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $464.00M 10-K · filed 2015-02-27 | $544.66M 10-Q · filed 2013-05-08 | -$58.00M derived: sum of 2 quarters · filed 2015-02-27 | $281.00M derived: sum of 3 quarters · filed 2015-02-27 | $692.00M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | -$522.00M 10-K · filed 2014-02-21 | -$183.00M derived: sum of 2 quarters · filed 2014-02-21 | $228.00M derived: sum of 3 quarters · filed 2014-02-21 | $237.00M 10-K · filed 2015-02-27 | $579.00M 10-K · filed 2014-02-21 | |||
| 2012-09-30 | $339.00M 10-K · filed 2014-02-21 | $338.92M 10-Q · filed 2013-11-07 | $750.00M derived: sum of 2 quarters · filed 2014-02-21 | $1.10B 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $411.00M 10-K · filed 2014-02-21 | $410.84M 10-Q · filed 2013-08-06 | $762.06M 10-Q · filed 2013-08-06 | |||||
| 2012-03-31 | $351.00M 10-K · filed 2014-02-21 | $351.21M 10-Q · filed 2013-05-08 | ||||||
| 2011-12-31 | $1.13B 10-K · filed 2014-02-21 | |||||||
| 2010-12-31 | $4.63B 10-K · filed 2011-02-18 | |||||||
| 2009-12-31 | $5.75B 10-K · filed 2011-02-18 | |||||||
| 2008-12-31 | $4.73B 10-K · filed 2011-02-18 | |||||||
| 2007-12-31 | $3.61B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |